



सामाजिक न्याय की दरकार

संतान आने वाली हो तो, शादी हो तो, उधम डालना हो या कही घूमने जाना हो तो हर जगह योजना बनाते है, कब क्या व कैसे करना या बजट क्या होगा. तीन दशक से हम युवा देश है का राग अलाप रहे है सही मे है, अब हमारी एक बहुत बड़ी आबादी वृद्धावस्था की १२ बढ़ रही है. बहुत लोगों के बच्चे विदेश मे व बाहर है अब इतनी बड़ी वृद्ध आबादी के लिए सरकार के पास कोई योजना ही नहीं है. पेंशन या व्यापारी हो तो धन तो हो सकता है पर इस उम्र मे मात्र धन पर्याप्त नहीं होता देख रेख भी चाहिए. पचास पार के लोग बहुत परेशान है कि संतान को रोक सकना सम्भव नहीं अब दोनों कामकाजी हो तो उनके पास जाने मे कोई तुक भी नहीं संयुक्त परिवार तो है ही नहीं, तो उनका चिंतित होना स्वाभाविक है.

सामाजिक न्याय विभाग को इसकी अच्छी तैयारी करनी चाहिए, व सभी पार्टी के घोषणापत्र मे भी इसे मुख्य स्थान मिलना चाहिए, मेडिकल साइंस के कारण ओसत उम्र भी बढ़ी है, तो दूसरी १२ अशुद्ध खानपान के कारण जोड़ व मांसपेशिया कमजोर हो रही है. सभी आजकल व्यायाम करते भी है, तो भी देख रेख करने की जरूरत होगी ही. यूँ संत जन् वृद्धाश्रम खुलने का विरोध करते परन्तु नये युग काल को देखते हुये इस १२ ध्यान देना जरूरी है, नोट तो जिए तब तक देता है, सामान्य सुविधाओं का वह अधिकारी भी है.

विश्वस्त आदमी नहीं मिलते हैं फिर अलजीमर व डेमेन्शिया जैसे रोग बढ़ रहे हैं, ये एक कड़वी सच्चाई है.वृद्ध हत्या भी आम हैं. कई दिन बाद बदबू आने पे पता लगता, निजी संस्थान तो बन भी रहे हैं पर जिन अस्सी करोड़ को भोजन दिया जा रहा वे गरीबी रेखा के नीचे हैं. सब अपना अधिकार मांग रहे. बहुत जरूरी हैं इस विषय को प्राथमिकता मे रखा जाय. अभी सब नगर निगम पचास वर्षीय प्लान बना रहे हैं, संसाधन व अन्न उत्पादन कम हो रहा, जंगल कट ही चुके तो इसे भी बढ़ी आपदा मान निराकरण किया जाये.समय पूर्व जगना जरूरी हैं. कुत्तो का हाल देख रहे हो सब।

26 से कांग्रेस सरकारी कार्यालयों का शुरू करेगी घेराव, ब्लाक अध्यक्षों की बैठक में लिया निर्णय



इन्दौर। आगामी 26 दिसंबर को डेली कॉलेज स्थित विद्युत मंडल कार्यालय के घेराव के साथ शहर कांग्रेस कमेटी द्वारा विभिन्न सरकारी कार्यालयों के अपने घेराव प्रदर्शन अभियान की शुरुआत की जाएगी। इसके लिए शहर कांग्रेस के कार्यवाहक अध्यक्ष देवेंद्र सिंह यादव और संगठन महासचिव संजय बाकलीवाल को प्रभावी बनाया गया है। यह निर्णय शहर कांग्रेस कमेटी द्वारा नवनिर्वाचित ब्लॉक अध्यक्षों की बैठक में लिया गया। कल शहर कांग्रेस कार्यालय गांधी भवन में आयोजित बैठक में शहर कांग्रेस अध्यक्ष चिंदू चौकसे और दीपू यादव ने ब्लाक अध्यक्षों की जिम्मेदारियों पर चर्चा की। बैठक में निर्णय लिया गया कि ब्लॉक अध्यक्षों को 26 दिसंबर से 28 जनवरी तक विभिन्न कार्यक्रम आयोजित करना है। इसी क्रम में 26 दिसंबर को डेली कॉलेज विद्युत मंडल का घेराव किया जाएगा। इसके बाद 29 दिसंबर को निगम झोन 8 का घेराव और 8 जनवरी को आबकारी कार्यालय का घेराव करेंगे। बैठक में जय हार्डिया, शैलेश गर्ग भी मौजूद रहे।

अंतिम पत्र

दोनों केबिनेट मंत्रियों में से किसकी बात को सही है ? समाचार ।

वित्त मंत्री जगदीश देवड़ा ने कहा है कि वित्तीय संकट नहीं बल्कि सरकार के पास पर्याप्त धन रहि है । टिप्पणी ।

शहरी विकास मंत्री विजयवर्गीय ने कहा है कि नगरीय निकायों से आय नहीं होने से प्रदेश की वित्तीय स्थिति ठीक नहीं है।



बी एल शर्मा
अकिंचन तराना-उज्जैन

कार्टून कोना...



बांग्लादेश में हालिया हिंसक घटनाओं पर गहरी चिंता व्यक्त

इंदौर। ऑल इंडिया पीस एंड सॉलिडैरिटी ऑर्गनाइजेशन (एप्सो), मध्य प्रदेश राज्य समिति, बांग्लादेश में हालिया हिंसक घटनाओं पर गहरी चिंता व्यक्त करती है। छात्र नेता हदी की मृत्यु के बाद हुई हिंसा, मीडिया संस्थानों व सांस्कृतिक धरोहरों पर हमले तथा अल्पसंख्यक युवक दीपू दास की हत्या लोकतांत्रिक मूल्यों और साम्प्रदायिक सौहार्द के लिए गंभीर खतरा है।

एप्सो अल्पसंख्यकों के विरुद्ध हिंसा और बढ़ती भारत-विरोधी बयानबाजी की कड़ी निंदा करता है तथा संयुक्त राष्ट्र द्वारा व्यक्त लोकतांत्रिक स्वतंत्रताओं, अल्पसंख्यक अधिकारों और पत्रकारों की सुरक्षा संबंधी चिंताओं का समर्थन करता है। एप्सो बांग्लादेश सरकार से दोषियों के विरुद्ध सख्त कार्रवाई और अल्पसंख्यकों व प्रेस की सुरक्षा सुनिश्चित करने की मांग करता है। साथ ही, भारत सरकार से अपील है कि वह संयमित और जिम्मेदार कूटनीतिक कदम उठाए ताकि भारत-बांग्लादेश के बीच शांति और आपसी विश्वास बना रहे।

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE BSE LIMITED ("BSE") AND "NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE", AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



SYMBIOTEC

SYMBIOTEC PHARMALAB LIMITED

Symbiotec Pharmalab Limited (our "Company") was incorporated as 'Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025 and a special resolution dated September 12, 2025 passed in the extraordinary general meeting of our Shareholders. Consequently the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre. For further details on the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 269 of the draft red herring prospectus dated December 19, 2025 ("DRHP").

Corporate Identity Number: U24232MP2002PLC015293; Website: www.symbiotec.com
Registered and Corporate Office: 385/2, Pigdamber, Rau, Mhow, Indore - 453 331, Madhya Pradesh, India
Contact Person: Sallil Jain, Company Secretary and Compliance Officer, Telephone: +91 731 667 6405; Email: secretarial@sybiotec.com

THE PROMOTERS OF OUR COMPANY: ANIL SATWANI, KASHISH SATWANI, SUSHIL SATWANI AND SATWANI HOLDINGS LLP

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹21,800.00 MILLION ("OFFER"). THE OFFER COMPRISES A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹1,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("OFFERED SHARES") AGGREGATING UP TO ₹20,300.00 MILLION, COMPRISING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹1,800.00 MILLION BY SATWANI HOLDINGS LLP (THE "PROMOTER SELLING SHAREHOLDER"), UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹12,500.00 MILLION BY ROSEWOOD INVESTMENTS AND UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹6,000.00 MILLION BY INDIA BUSINESS EXCELLENCE FUND - III (THE "INVESTOR SELLING SHAREHOLDERS"), AND TOGETHER WITH THE PROMOTER SELLING SHAREHOLDER, THE "SELLING SHAREHOLDERS" AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE". THE OFFER WILL CONSTITUTE [●]% OF THE POST-OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

IN ACCORDANCE WITH AND SUBJECT TO REGULATION 33 OF THE SEBI ICDR REGULATIONS, THE OFFER MAY INCLUDE A RESERVATION OF UP TO [●] EQUITY SHARES (OF FACE VALUE OF ₹2 EACH), AGGREGATING UP TO ₹[●] MILLION (CONSTITUTING UP TO 5% OF THE POST OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER SHALL CONSTITUTE [●]% AND [●]%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, MAY OFFER A DISCOUNT OF UP TO [●] (EQUIVALENT TO ₹[●] PER EQUITY SHARE) TO THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING UNDER THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A FURTHER ISSUE OF SPECIFIED SECURITIES AS MAY BE PERMITTED UNDER APPLICABLE LAW, AT ITS DISCRETION, AGGREGATING UP TO ₹300.00 MILLION (THE "PRE-IPO PLACEMENT"), PRIOR TO THE FILING OF THE RED HERRING PROSPECTUS. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED ("SCRR"). THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER OR THAT THE OFFER MAY BE SUCCESSFUL AND WILL RESULT IN THE LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND PROSPECTUS, AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

THE FACE VALUE OF THE EQUITY SHARE IS ₹2 EACH. THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND, THE MINIMUM BID LOT AND THE EMPLOYEE DISCOUNT, IF ANY, WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), AND ALL EDITIONS OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER), HINDI ALSO BEING THE REGIONAL LANGUAGE OF MADHYA PRADESH WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID / OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE LIMITED AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED FOR UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid / Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid / Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company may, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid / Offer Period for a minimum of one Working Day, subject to the Bid / Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid / Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks ("SCSBs"), Designated Intermediaries and the Sponsor Bank(s), as applicable.

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957 ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs", and such portion, the "QIB Portion", provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as under: (i) 33.33% for the domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the price at which allocation will be made to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations. Any under-subscription in the reserved category specified in clause (i) above may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (the "Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to QIB Bidders (other than Anchor Investors) including Mutual Funds subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to all QIBs. Further, not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders (out of which one-third of the portion available to Non-Institutional Bidders shall be reserved for Bidders with an application size of more than ₹0.20 million and up to ₹1.00 million and two-thirds shall be reserved for Bidders with an application size of more than ₹1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to Bidders in the other sub-category) and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders, other than Anchor Investors, are required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account and UPI ID in case of UPI Bidders, as applicable, pursuant to which their corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For further details, see "Offer Procedure" on page 473 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP dated December 19, 2025 with the SEBI and the Stock Exchanges. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with the SEBI has been made available to the public for comments, if any, for a period of at least 21 days from the date of publication of public announcement in accordance with Regulation 26(2) of SEBI ICDR Regulations. The DRHP has been filed by hosting it on the website of the Company at www.symbiotec.com, website of the SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e., BSE and NSE at www.bseindia.com and www.nseindia.com, respectively and the websites of the BRLMs, i.e., JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.jmfi.com, www.avendus.com, www.motilaloswalgroup.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Our Company hereby invites, the public to give comments on the DRHP filed with the SEBI and the Stock Exchanges with respect to disclosures made in the DRHP. The public is requested to send a copy of their comments to the SEBI, the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned below in relation to the Offer. All comments must be received by the SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer at their respective addresses mentioned below on or before 5.00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares have not been recommended or approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 42 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus has been filed with the RoC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the DRHP. The Equity Shares, when offered through the Red Herring Prospectus, are proposed to be listed on the mainboard of BSE and NSE.

For details of the share capital, capital structure of our Company, the names of the signatories to the Memorandum of Association and the number of shares of our Company subscribed by them, please see the section "Capital Structure" on page 112 of the DRHP. The liability of members of our Company is limited. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section "History and Certain Corporate Matters" on page 269 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER
JM Financial Limited 7 th Floor, Energy Appasaheb Marathe Marg Prabhadevi, Mumbai 400 025, Maharashtra, India Telephone: +91 22 8630 3030 E-mail: symbiotec ipo@jmfi.com Investor Grievance email: grievance.fbd@jmfi.com Website: www.jmfi.com Contact Person: Prachee Dhuri SEBI Registration No.: INM000010361	Avendus Capital Private Limited Platina Building, 9 th Floor, 901, Plot No C-59, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India Telephone: +91 22 6648 0050 Email: symbiotec ipo@avendus.com Investor grievance email: investor grievance@avendus.com Website: www.avendus.com Contact person: Sarthak Sawa/Shagun Lalwani SEBI Registration No.: INM000011021	Motilal Oswal Investment Advisors Limited* Motilal Oswal Tower, Rahmtilulahi Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai - 400 025, Maharashtra, India Telephone: +91 22 7193 4380 E-mail: sp.i.ipo@motilaloswal.com Investor Grievance E-mail: moiaipredressal@motilaloswal.com Website: www.motilaloswalgroup.com Contact Person: Kunal Thakkar/Vaidhav Shah SEBI Registration No.: INM000011005	Nomura Financial Advisory and Securities (India) Private Limited Ceeljay House, Level 11, Plot F, Shiv Sagar Estate, Dr. Annie Besant Marg, Worli, Mumbai - 400 018, Maharashtra, India Telephone: +91 22 4037 4037 E-mail: symbiotec ipo@nomura.com Investor Grievance E-mail: investorgrievances-in@nomura.com Website: www.nomuraholdings.com/company/group/asia/india/index.html Contact Person: Vishal Kanjani/Chirag Shah SEBI Registration No.: INM000011419	MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India Telephone: +91 810 811 4949 Email: symbiotecpharmalab ipo@in.mprms.mufg.com Investor grievance email: symbiotecpharmalab ipo@in.mprms.mufg.com Website: www.in.mprms.mufg.com Contact person: Shanti Gopalakrishnan SEBI Registration No.: INR000004058

COMPANY SECRETARY AND COMPLIANCE OFFICER

Sallil Jain, 385/2, Pigdamber, Rau, Mhow, Indore - 453 331, Madhya Pradesh, India; Telephone: +91 731 667 6405; Email: secretarial@sybiotec.com

*In compliance with the proviso to regulation 21A(1) and explanation (iii) to regulation 21A(1) of the SEBI Merchant Bankers Regulations., and regulation 23(3) of the SEBI ICDR Regulations, Motilal Oswal Investment Advisors Limited will be involved only in marketing the Offer. Motilal Oswal Investment Advisors Limited has signed the due diligence certificate and has been disclosed as a BRLM for the Offer.

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

Place: Madhya Pradesh, India
Date: December 19, 2025

For Symbiotec Pharmalab Limited
on and behalf of the Board of Directors
Sd/-
Sallil Jain
Company Secretary and Compliance Officer

Symbiotec Pharmalab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the DRHP dated December 19, 2025 with the SEBI and the Stock Exchanges. The DRHP is available on the website of the Company at www.symbiotec.com, SEBI at www.sebi.gov.in, as well as on the websites of the BRLMs, i.e., JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.jmfi.com, www.avendus.com, www.motilaloswalgroup.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively and the websites of National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 42 of the DRHP and the details set out in the Red Herring Prospectus, when filed. Any potential investors should not rely on the DRHP for making any investment decision.

This announcement is not an offer of securities for sale in the United States or elsewhere. This announcement has been prepared for publication in India only and is not for publication or distribution, directly or indirectly, in or into the United States. The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to the private placement exemption set out in Section 4(a) of the U.S. Securities Act, and (b) outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where those offers and sales are made.

Adfactors

